-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Biotech Q3 Net Loss Narrows 74% to $6.49 Million

PUBT·11/16/2026 12:32:39
Listen to the news
Moleculin Biotech Q3 Net Loss Narrows 74% to $6.49 Million
  • Moleculin Biotech’s third-quarter 2026 net loss narrowed 74% year over year to $6.49 million.
  • Research and development expenses rose 20% to $4.49 million, primarily due to MIRACLE clinical trial activities.
  • Cash and cash equivalents totaled $7.29 million at September 30, 2026.
  • Treatment finished for all 90 patients in Part A of the pivotal MIRACLE trial evaluating Annamycin for relapsed or refractory AML.
  • Comprehensive Part A data remain expected in Q1 2027, with Part B planned to begin in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160730PRIMZONEFULLFEED9878017) on November 16, 2026, and is solely responsible for the information contained therein.